# A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Source: https://onco.cc/trials/nct06481592/  
OnCo record `nct06481592` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lifileucel in endometrial cancer, run by Iovance Biotherapeutics, Inc., now recruiting.

## Summary

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. is a phase 2 interventional study registered as NCT06481592 by Iovance Biotherapeutics, Inc., with 60 participants planned, started 2024-10-29 and due to reach its primary completion in 2028-05. Interventions recorded: Lifileucel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06481592
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.
- Sponsor: Iovance Biotherapeutics, Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06481592: https://clinicaltrials.gov/study/NCT06481592

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Lifileucel](https://onco.cc/drugs/lifileucel/)
- companies: [Iovance Biotherapeutics](https://onco.cc/companies/iovance/)

---
JSON: https://onco.cc/api/v1/entities/nct06481592.json